XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

Core Viewpoint - XOMA Royalty Corporation has successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash, along with a contingent value right, resulting in Generation Bio becoming a wholly owned subsidiary of XOMA Royalty [1][3]. Group 1: Tender Offer Details - The tender offer expired on February 6, 2026, with 4,722,533 shares of Generation Bio common stock validly tendered, representing approximately 70% of the outstanding shares [2]. - All conditions of the tender offer were satisfied or waived, allowing XOMA Royalty to accept for payment all validly tendered shares [2]. Group 2: Merger and Aftermath - Following the tender offer, XRA 7 Corp., a subsidiary of XOMA Royalty, merged with Generation Bio, converting all untendered shares into the right to receive the offer price [3]. - Generation Bio's common stock ceased trading on Nasdaq after the merger, and plans are in place for the shares to be delisted and deregistered [3]. Group 3: Company Overview - XOMA Royalty is a biotechnology royalty aggregator that helps biotech companies by acquiring potential future economics associated with therapeutic candidates [5]. - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their drug candidates or for general corporate purposes [5].